By Evolve Ltd.
To get in touch with Evolve Ltd., simply fill out the form below.
Subscribe to Supplier
Evolve to distribute Saphetor NGS solutions
Luqa, Malta: – Life sciences environment specialist Evolve Ltd (Evolve) has finalized a distribution agreement with Swiss-based Saphetor SA, a precision medicine company that is a leader in diagnostic and bioinformatics solutions for clinical Next Generation Sequencing (NGS).
Under the agreement, Evolve will become distribution and support agents for market-leading innovative solutions such as Illumina and Saphetor’s VarSome Clinical, a clinically certified platform for interpretation of NGS data.
NGS bioinformatics services
This significantly extends Evolve’s portfolio of tools and services for a wide range of its clients employing NGS technologies for clinical as well as for research purposes.
Evolve Ltd. Managing Director Christopher Busuttil Delbridge, commented: ‘This new partnership helps us to deliver high-quality, state-of-the-art bioinformatics services in the clinical and research fields, along with our wide portfolio of assays for Cancer genetics, reproductive healthcare, library preparation kits and reagents for NGS.’
Saphetor founder and CEO Andreas Massouras added: ‘We are excited to count Evolve among our regional distributors for our bioinformatics tools, and we are prepared to work closely with their team to provide their clients with an integrated solution for diagnostics purposes.’
About Evolve Ltd.
Evolve Ltd, is a Malta-based solution provider and project integrator operating in the Mediterranean and sub-Saharan African region. Servicing all scientific workspaces Evolve professionals offer Design, Consultancy, Sourcing and Maintenance services to healthcare and industrial communities. Having been the ones to introduce NGS technology in Malta, Evolve is best positioned to continue building on its knowledge and services to further scientific advancement in this sector in Malta too. Empowered specialists give faster and more accurate results for the benefit of patients.
Evolve offers a holistic service that draws on four principal areas of expertise, in the design, installation and equipment, personnel training and maintenance of laboratory and research facilities and equipment.
Evolve Ltd. is part of the Attard & Co. Group of Companies and traces its origins to Attard’s setting up in 1956 of Medical and Scientific Equipment and Supplies (MSES) to cater for its scientific products. During the 1990s, under the leadership of Christopher Busuttil Delbridge, Evolve’s current Managing Director, MSES changed its business model, centered on a vision to become a recognized, award-winning, world-class thought leader and influencer on the international scientific and healthcare laboratory market.
In 2006, following Malta’s accession to the EU, MSES Department was rebranded as Evolve Ltd., an independent Attard subsidiary tasked with serving the scientific community. Within five years, it had developed three operating departments: Medical & Diagnostics, Scientific Services and Technical Services.
Evolve currently employs some 30 people, mostly scientists and technical experts.
Further information at: www.evolveltd.eu
About Saphetor SA
Saphetor SA, is a Swiss precision-medicine company dedicated to large-scale identification and interpretation of human genetic variants by leveraging proprietary algorithms and expert domain knowledge.
Saphetor is the creator of VarSome, a suite of intuitive and data-driven bioinformatics solutions both for clinicians and researchers. VarSome.com search engine and professional community is freely accessible, featuring a widely-recognized community-driven knowledge base that enables flexible queries across more than 30 genetic and genomic data resources. VarSome Pro and VarSome Clinical are professional editions of VarSome with powerful functionality and further sophisticated data-mining and analysis tools.
While VarSome Pro serves researchers, VarSome Clinical is a clinically-accredited platform allowing fast and accurate variant discovery, annotation, and interpretation of NGS data for whole genomes, exomes, and gene panels, which helps clinicians reach faster and more accurate diagnoses and treatment decisions for genetic conditions.